Biotech Companies Driving Psychedelics Industry Forward with Key Research

NEW YORK, April 13, 2021 /PRNewswire/ -- As an urgent public mental health crisis forces research institutions and governments to seriously examine unconventional mental health solutions, psychedelic assisted therapies are showing huge potential. Now, biotech companies have seen the opportunity, and psychedelics companies are diving into further research to seek out mental health solutions for conditions such as depression, PTSD, and suicidal ideation. Some companies like Mydecine Innovations Group (NEO:MYCO) (OTCPK:MYCOF), Compass Pathways (NASDAQ:CMPS), Minerco Inc. (OTCPK:MINE), Numinus Wellness (TSXV:NUMI) (OTCPK:LKYSF), and Seelos Therapeutics (NASDAQ:SEEL) are also looking into natural medicine initiatives to improve the quality of life of individuals struggling with mental health disorders

Mydecine Innovations Group Develops Lead Novel Drug Candidates

As biotech and life sciences companies become the driving force behind psychedelic research, Mydecine Innovations Group (NEO:MYCO) (OTC:MYCOF) is becoming a leader in this space. Mydecine is dedicated to the research, development, and commercialization of psilocybin-based therapies. The company holds a full Health Canada Schedule 1 Controlled Drugs and Substances Dealer's Licence and operates a state-of-the-art mycology lab in Denver, Colorado. The company has facilitated numerous studies and development initiatives in-house and in collaboration with top research institutions.

On April 7, Mydecine announced that the company's research team has developed four lead novel drug candidates and that Mydecine is currently preparing for Pre-Investigational New Drug (IND) meetings with the FDA and Health Canada. The four compounds include pure psilocybin from natural fungal sources, an entactogenic compound created with the goal of reducing harm and improving the safety profile compared to traditional MDMA, a psilocybin-based formula with reduced potential to trigger anxiety in patients, and a tryptamine compound that could be delivered transdermally with precision dosing and a shortened duration.

"Our first four novel drug candidates deliver on our long-term strategic road map for drug development with regular milestones that iteratively add value over time. By increasing the complexity of these compounds, we are increasing layers of patents applied, which in turn, also adds pharmaceutical value to the drug candidates," Mydecine Co-Founder and CEO Joshua Bartch said in the company's release. "The promise of these molecules is undeniable. By providing scalable, more stable compounds and delivery mechanisms for research and development, it means that new treatments for previously untreatable mental illnesses are close at hand."

On March 23, Mydecine announced that the company had graduated to the NEO Exchange. Bartch said in Mydecine's release that the move will increase transparency and visibility for the company as it pursues its research and development goals.

"Mydecine is paving the way for incredible breakthroughs and we are thrilled to support their success as the Company's listing exchange of choice," Jos Schmitt, President and CEO of NEO commented in Mydecine's release. "Psychedelic therapeutic treatments have the potential to offer life-altering relief to millions of people around the world who suffer from mental health and addiction issues. We look forward to providing Mydecine with enhanced visibility and greater access to capital on our tier-one exchange so they can continue the great work they are doing."

Biotech Companies Gear Up for Key Research

Across the industry, psychedelics-focused biotech companies are gearing up for research that could help shape the future of mental health treatment. On March 9, Numinus Wellness (TSXV:NUMI) (OTC:LKYSF) announced plans to significantly expand its psychedelics research laboratory by the end of the year.

Compass Pathways (NASDAQ:CMPS) announced on March 23 that the company had been granted two new patents by the US Patent and Trademark Office covering synthetic psilocybin formulations developed by Compass for treatment of major depressive disorder and treatment-resistant depression. The company says that these patents represent a critical milestone in its efforts to establish a new evidence-based option to help patients with depression and will aid the company's clinical research.

In January, Jamaica-based biotech company Minerco Inc. (OTC:MINE) was acquired by a specialized investment firm with plans to immediately transition the company to the psilocybin therapeutics market with a focus on research and development. Earlier in January, Minerco announced that the company had partnered with Lazurus Holistic to serve as psilocybin experts to grow and develop a unique strain of mushrooms specific to Jamaica.

Biopharmaceutical company Seelos Therapeutics (NASDAQ:SEEL) announced on March 5 that the company had completed its enrollment of patients in Part one of its registrational Proof of Concept study of intranasal racemic ketamine for Acute Suicidal Ideation and Behavior in patients with Major Depressive Disorder.  The company says that it expects to release key open-label data by the second quarter of 2021

Promising research is driving momentum in the psychedelic therapeutics industry, and companies like Mydecine Innovations Group are building on that momentum with their own research and development.

Click here to find out more about Mydecine Innovations Group.

Disclaimer:  Microsmallcap.com (MSC) is the source of the Article and content set forth above. MSC owns and operates Streetsignals.com.  References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MSC or any company mentioned herein. The commentary, views and opinions expressed in this release by MSC are solely those of MSC and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MSC and FNM for any investment decisions by their readers or subscribers. MSC and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author (MSC), and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author (MSC) has not independently verified or otherwise investigated all such information. None of the Author, MSC, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment. FNM was not compensated by any public company mentioned herein to disseminate this press release but was compensated twenty five hundred dollars by MSC, a non-affiliated third party to distribute this release on behalf of Mydecine Innovations Group Inc.

FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MSC and FNM undertake no obligation to update such statements.

Media Contact:
FN Media Group, LLC
[email protected]
+1(561)325-8757

SOURCE Microsmallcap.com